Merck launches SEQUIVITY vaccine for swine health
USAgNet - 03/27/2024
Merck Animal Health introduces SEQUIVITY with Microsol Diluvac Forte, a groundbreaking vaccine for swine. Utilizing advanced RNA Particle Technology and MDF adjuvant, this vaccine provides safe and precise protection against a range of swine diseases.
The SEQUIVITY platform offers swine producers a revolutionary approach to vaccination, with tailored solutions for specific herd needs. By combining RNA Particle Technology with MDF adjuvant, Merck creates vaccines that enhance immune response and provide long-lasting immunity.
Unlike traditional vaccines that can take years to develop, SEQUIVITY offers a rapid response to evolving pathogens. Through careful selection of gene sequences, Merck can quickly produce targeted vaccines, addressing emerging disease challenges with precision.
Dr. Jeremy Maurer, Associate Director of U.S. Livestock Insights and Outcomes for Merck Animal Health, emphasizes the company's commitment to innovation in animal health. SEQUIVITY builds on Merck's legacy of vaccine development, offering swine producers and veterinarians a powerful tool to protect herd health.
The SEQUIVITY vaccine comes in two bottles, a frozen antigen bottle and a diluent bottle, mixed at the point of use. This flexible formulation allows for easy administration and customized dosing for individual herds.
Merck Animal Health provides comprehensive support for SEQUIVITY users, including a web-based dashboard for data-driven decision-making. Swine producers and veterinarians can access relevant insights to address herd-specific needs effectively.
- US ethanol production dips to seasonal low
- USDA boosts clean energy with $238 million investment
- Optimizing needle practices for healthier cattle
- New USDA school meal standards boost child nutrition
- Bioinformatics revolutionizes animal science
- Bayer partners with AlphaBio to launch innovative bioinsecticide by 2028
- Bird flu crisis hits US farms - Urgent biosecurity measures needed
